FRIDAY, JANUARY 24
8:00 - 9:00 AM
Protein therapeutics is a fast-growing global market. As the science improves, so does the complexity of the R&D organization. Ensuring product quality plus speed to market requires insights from stakeholders working across the stages of protein science R&D. Join experts representing this PepTalk pipeline, peers, and colleagues for an interactive roundtable discussion. Topics include highlights from the week’s presentations, new technologies and strategies, challenges, and future trends.
To see discussion table topics for the Monday BuzZ Sessions with Refreshments (January 20 at 3:15 - 4:30 pm), please click here.
Discussion Table Topics
Room: Sapphire & Aqua Foyers
Table 12: Protein Engineering & Development – Week in Review
Samantha Phan, Consultant Biologist, Protein BioSciences, Eli Lilly and Company
- What were your favorite presentations this week?
- How will the new constructs and technologies presented at PepTalk impact your work?
- What are the challenges to be overcome in implementing these new approaches?
- Emerging trends that will impact protein engineering and development
Table 13: Antibody Therapeutics – Week in Review
Steffen Goletz, PhD, Professor and Deputy Head, Biotechnology and Biomedicine, and Vice Director, Institute of Bioengineering, Technical University of Denmark
- Tumor targeting
- New modalities
- Combination and CAR T cell therapy
- Predictive modeling
- Novel antibody formats
Table 14: Cell & Gene Therapies – Week in Review
Jim Richardson, PhD, Senior Science and Standards Liaison, Global Biologics, United States Pharmacopeia
- Challenges and opportunities – which talks and speakers motivated you?
- New technologies and learnings during the week that you can apply in your work
- Manufacturing and scale-up insights
- Supply chain challenges
Table 15: Formulation & Stability – Week in Review
Tanvir Tabish, MSc, Head of Formulation Development, Formulation, Fill and Finish, Takeda
- Which talks and speakers inspired you?
- Review of practical strategies in lyophilization of novel formulation
- Insights on formulation development of novel molecules and cell and gene therapies
Table 16: Analytics & Impurities – Week in Review
Thomas Laue, PhD, Professor Emeritus, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire
- Which talks and speakers inspired you?
- Review of practical strategies in mitigating aggregation in biologics
- Insights on management of impurities
- Formulation development of novel molecules and cell and gene therapies
Table 17: Process Technologies & Purification – Week in Review
Renaud Vincentelli, PhD, Head, High-Throughput Protein Production, Structural Biology Core, Architecture et Fonction des Macromolécules Biologiques (AFMB), UMR, CNRS – Aix-Marseille University
- Managing and analyzing data
- High-throughput screening and assays
- Continuous processing
- Affinity tags
- High-throughput analytics
Table 18: Biotherapeutic Expression & Production – Week in Review
Richard Altman, MS, Field Application Scientist, Protein Expression, Biosciences Division, Life Sciences Solutions Group, Thermo Fisher Scientific
- Protein therapeutics is a fast-growing global market. Ensuring product quality plus speed to market requires collaboration from stakeholders working across the stages of protein science R&D
- Join us in an interactive roundtable discussion as we review and wrap up the Biotherapeutic Expression & Production Pipeline
- Topics will include highlights from the week’s presentations, new technologies and strategies, challenges, and future trends
Table 19: Systems to Screen B and T Cell Repertoires
Vu Truong, PhD, CSO & CEO, R&D, Aridis Pharmaceuticals, Inc.
- Cell sorting systems
- Nanodroplet systems
- Microfluidic systems
- Culture microarrays
Table 20: Application of Artificial Intelligence / Machine Learning in Biopharmaceutical Development
Reza Esfandiary, Associate Director, Early Stage Formulation Sciences, BioPharmaceutical Development, AstraZeneca
- Accelerating drug discovery through the power of AI
- How to use it and challenges
- What are successful pharma companies doing today to prepare for a data-fueled, machine learning future?
Table 21: Challenges in Development of Cell Therapies for Solid Tumors
Sandro Matosevic, PhD, Assistant Professor, Department of Industrial and Physical Pharmacy, Purdue University
- Sourcing
- Manufacturing
- Genetic engineering
Table 22: Product Differentiation through Creative Formulation and Smart Delivery Devices
Jan Jezek, PhD, CSO, Arecor Ltd.
- Product strategy throughout the development process (defining TPP, developability assessment, etc.)
- Role of formulation in achieving the TPP
- Life cycle management – approaches to protecting existing products (timing, defining improved TPP, intellectual property, etc.)
Table 23: Data Science Tools for Process Characterization
NEW: Spin Wang, MS, Co-Founder and CEO, TetraScience
- Can we rely on high-throughout techniques as representative scale-down models? Can we prove ideal scale-down models at all?
- Data and knowledge recycle strategies: how is suitable data and process understanding transferred from one project/product to another?
- Best strategies and tools for managing data
Table 24: Expression Hosts for Integral Membrane Receptors
Alexei Yeliseev, PhD, Staff Scientist, Group Leader, LMBB, National Institute on Alcohol Abuse and Alcoholism, National Institute of Health
- Different expression hosts: advantages and disadvantages
- Significance of post-translational modifications
- Effect of host on stability of target protein
- Expression hosts and fusion partners